米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据

doi:10.3969/j.issn.1673-5765.2026.05.003

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (5): 533-542.DOI: 10.3969/j.issn.1673-5765.2026.05.003

米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据

杨千千^1*，张眉扬^1*，陆瑶¹，周东杨¹，王正一蕾¹，单舒乙¹，刘晨辉²，王伊龙^{1，3，4，5，6}，管玲^1，7，8（*第一作者）

1北京 100070 首都医科大学附属北京天坛医院神经病学中心
2郑州 450052 郑州大学第一附属医院神经内科
3北京 102206 北京脑科学与类脑研究所
4北京 100070 国家神经疾病医学中心
5北京 100069 首都医科大学人脑保护高精尖创新中心
6北京 100070 神经系统疾病国家临床医学研究中心
7北京 100081 北京理工大学前沿交叉科学院
8温哥华 V6H3N1 不列颠哥伦比亚大学医学系

收稿日期:2026-01-18 修回日期:2026-05-05 接受日期:2026-05-12 出版日期:2026-05-20 发布日期:2026-05-20
通讯作者: 管玲 lguanm@gmail.com
基金资助:
国家自然科学基金(82271516；81801187)
备注:更正：本文因故遗漏基金项目信息，现补充如下：国家自然科学基金(82271516；81801187)。更正信息已刊登于2026年6期第729页。

Research Progress on the Anti-Neuroinflammatory Effects and Brain Cytoprotection of Minocycline in Acute Ischemic Stroke: From Mechanisms to Clinical Evidence

YANG Qianqian^1*, ZHANG Meiyang^1*, LU Yao¹, ZHOU Dongyang¹, WANG Zhengyilei¹, Shan Shuyi¹, LIU Chenhui², WANG Yilong^1,3,4,5,6, GUAN Ling^1,7,8(*contributed equally)

1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
2Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
3Chinese Institute for Brain Research, Beijing 102206, China
4National Center for Neurological Disorders, Beijing 100070, China
5Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China
6China National Clinical Research Center for Neurological Diseases, Beijing 100070, China
7School of Interdisciplinary Science, Beijing Institute of Technology, Beijing 100081, China
8Department of Medicine, The University of British Columbia, Vancouver V6H3N1, Canada

Received:2026-01-18 Revised:2026-05-05 Accepted:2026-05-12 Online:2026-05-20 Published:2026-05-20
Contact: GUAN Ling, E-mail: lguanm@gmail.com

摘要/Abstract

摘要： 急性缺血性卒中是导致残疾和死亡的重要病因之一。尽管再灌注治疗及二级预防策略不断完善，仍有部分患者遗留不同程度的神经功能障碍。神经炎症反应贯穿急性缺血性卒中的发生、进展和修复过程，近年来已成为脑细胞保护治疗的重要干预靶点。米诺环素作为一种经典的四环素类抗生素，除抗菌作用外，还具有调节小胶质细胞活化、抑制炎症因子释放、降低基质金属蛋白酶活性、减少外周免疫细胞向中枢浸润等多靶点抗神经炎症作用。既往临床前实验显示，米诺环素可在多种脑缺血动物模型中缩小梗死体积、减轻神经功能损伤。早期临床探索性研究提示，米诺环素用于急性缺血性卒中总体安全且可耐受，但疗效尚不一致。近期大型随机对照试验米诺环素治疗中重度急性缺血性卒中患者的有效性及安全性（efficacy and safety of minocycline in patients with moderate to severe acute ischemic stroke，EMPHASIS）研究显示，短程米诺环素治疗可改善急性缺血性卒中患者90 d功能预后，且未明显增加安全性风险。未来仍需围绕优势获益人群识别，最佳给药时间窗、剂量与疗程优化，联合再灌注治疗评估，新型递送策略制订，以及影像学与生物标志物评价体系等方面开展深入研究，以进一步明确米诺环素在急性缺血性卒中治疗中的临床定位和转化价值。

文章导读： 本文综述了米诺环素改善急性缺血性卒中预后的研究进展，并探讨了其抗神经炎症与脑细胞保护的潜在机制，以期为临床医师在急性缺血性卒中早期使用脑细胞保护剂提供参考。

关键词: 急性缺血性卒中; 米诺环素; 神经炎症; 脑细胞保护

Abstract: Acute ischemic stroke is a major cause of disability and mortality. Despite continuous improvements in reperfusion therapy and secondary prevention strategies, some patients still experience varying degrees of neurological dysfunction after stroke. Neuroinflammation is involved in the onset, progression, and recovery of acute ischemic stroke and has emerged as an important therapeutic target for brain cytoprotection in recent years. Minocycline, a classic tetracycline antibiotic, exerts multiple anti-neuroinflammatory effects beyond its antimicrobial activity, including modulation of microglial activation, suppression of inflammatory cytokine release, inhibition of matrix metalloproteinase activity, and attenuation of peripheral immune-cell infiltration into the central nervous system. Preclinical studies have shown that minocycline reduces infarct volume and attenuates neurological deficits in various animal models of cerebral ischemia. Preliminary clinical studies have suggested that minocycline is generally safe and well tolerated in patients with acute ischemic stroke, although evidence for its efficacy remains inconsistent. More recently, a large-scale randomized controlled trial—EMPHASIS (efficacy and safety of minocycline in patients with moderate to severe acute ischemic stroke) trial showed that short-course minocycline treatment improves 90-day functional outcomes in patients with acute ischemic stroke, without significantly increasing safety risks. Future studies should focus on identifying the target populations most likely to benefit, optimizing the therapeutic time window, dose, and treatment duration, evaluating combination strategies with reperfusion therapy, and developing novel drug-delivery approaches as well as imaging and biomarker-based evaluation systems, thereby clarifying the clinical role and translational value of minocycline in acute ischemic stroke.

Key words: Acute ischemic stroke; Minocycline; Neuroinflammation; Brain cytoprotection

中图分类号:

杨千千, 张眉扬, 陆瑶, 周东杨, 王正一蕾, 单舒乙, 刘晨辉, 王伊龙, 管玲. 米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据[J]. 中国卒中杂志, 2026, 21(5): 533-542.

YANG Qianqian, ZHANG Meiyang, LU Yao, ZHOU Dongyang, WANG Zhengyilei, Shan Shuyi, LIU Chenhui, WANG Yilong, GUAN Ling. Research Progress on the Anti-Neuroinflammatory Effects and Brain Cytoprotection of Minocycline in Acute Ischemic Stroke: From Mechanisms to Clinical Evidence[J]. Chinese Journal of Stroke, 2026, 21(5): 533-542.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.chinastroke.org.cn/CN/10.3969/j.issn.1673-5765.2026.05.003

https://www.chinastroke.org.cn/CN/Y2026/V21/I5/533

参考文献

[1] ZHOU M G，WANG H D，ZHU J，et al. Cause-specific mortality for 240 causes in China during 1990-2013：a systematic subnational analysis for the global burden of disease study 2013[J]. Lancet，2016，387（10015）：251-272.
[2] WANG W Z，JIANG B，SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017，135（8）：759-771.
[3] PRABHAKARAN S，GONZALEZ N R，ZACHRISON K S，et al. 2026 guideline for the early management of patients with acute ischemic stroke：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2026[2026-03-15]. https://doi.org/10.1161/STR.0000000000000513.
[4] GREFKES C，FINK G R. Recovery from stroke：current concepts and future perspectives[J/OL]. Neurol Res Pract，2020，2：17[2026-03-15]. https://doi.org/10.1186/s42466-020-00060-6.
[5] SHICHITA T，OOBOSHI H，YOSHIMURA A. Neuroimmune mechanisms and therapies mediating post-ischaemic brain injury and repair[J]. Nat Rev Neurosci，2023，24（5）：299-312.
[6] ZHAO K M，WANG P W，TANG X G，et al. The mechanisms of minocycline in alleviating ischemic stroke damage and cerebral ischemia-reperfusion injury[J/OL]. Eur J Pharmacol，2023，955：175903[2026-03-15]. https://doi.org/10.1016/j.ejphar.2023.175903.
[7] QIN C，YANG S，CHU Y H，et al. Signaling pathways involved in ischemic stroke：molecular mechanisms and therapeutic interventions[J/OL]. Signal Transduct Target Ther，2022，7（1）：215[2026-03-15]. https://doi.org/10.1038/s41392-022-01064-1.
[8] DELONG J H，OHASHI S N，O’CONNOR K C，et al. Inflammatory responses after ischemic stroke[J]. Semin Immunopathol，2022，44（5）：625-648.
[9] WANG X，XUAN W，ZHU Z Y，et al. The evolving role of neuro‐immune interaction in brain repair after cerebral ischemic stroke[J]. CNS Neurosci Ther，2018，24（12）：1100-1114.
[10] YRJÄNHEIKKI J，TIKKA T，KEINÄNEN R，et al. A tetracycline derivative，minocycline，reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window[J]. Proc Natl Acad Sci U S A，1999，96（23）：13496-13500.
[11] CHEN M，ONA V O，LI M，et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease[J]. Nat Med，2000，6（7）：797-801.
[12] ZHU S，STAVROVSKAYA I G，DROZDA M，et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice[J]. Nature，2002，417（6884）：74-78.
[13] JIN Z Q，LIANG J，WANG J，et al. Mcp-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo[J/OL]. J Neuroinflammation，2015，12：39[2026-03-15]. https://doi.org/10.1186/s12974-015-0264-1.
[14] MACHADO L S，SAZONOVA I Y，KOZAK A，et al. Minocycline and tissue-type plasminogen activator for stroke：assessment of interaction potential[J]. Stroke，2009，40（9）：3028-3033.
[15] YANG Y R，SALAYANDIA V M，THOMPSON J F，et al. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery[J/OL]. J Neuroinflammation，2015，12：26[2026-03-15]. https://doi.org/10.1186/s12974-015-0245-4.
[16] MURATA Y，ROSELL A，SCANNEVIN R H，et al. Extension of the thrombolytic time window with minocycline in experimental stroke[J]. Stroke，2008，39（12）：3372-3377.
[17] YAMASAKI T，HATORI A，ZHANG Y D，et al. Neuroprotective effects of minocycline and KML29，a potent inhibitor of monoacylglycerol lipase，in an experimental stroke model：a small-animal positron emission tomography study[J]. Theranostics，2021，11（19）：9492-9502.
[18] BERGOLD P J，FURHANG R，LAWLESS S. Treating traumatic brain injury with minocycline[J]. Neurotherapeutics，2023，20（6）：1546-1564.
[19] VELLIMANA A K，ZHOU M L，SINGH I，et al. Minocycline protects against delayed cerebral ischemia after subarachnoid hemorrhage via matrix metalloproteinase‐9 inhibition[J]. Ann Clin Transl Neurol，2017，4（12）：865-876.
[20] LAMPL Y，BOAZ M，GILAD R，et al. Minocycline treatment in acute stroke：an open-label，evaluator-blinded study[J]. Neurology，2007，69（14）：1404-1410.
[21] SWITZER J A，HESS D C，ERGUL A，et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke[J]. Stroke，2011，42（9）：2633-2635.
[22] SWITZER J A，SIKORA A，ERGUL A，et al. Minocycline prevents IL-6 increase after acute ischemic stroke[J]. Transl Stroke Res，2012，3（3）：364-368.
[23] BLACKER D J，PRENTICE D，ALVARO A，et al. Reducing haemorrhagic transformation after thrombolysis for stroke：a strategy utilising minocycline[J/OL]. Stroke Res Treat，2013：362961[2026-03-15]. https://doi.org/10.1155/2013/362961.
[24] PADMA SRIVASTAVA M V，BHASIN A，BHATIA R，et al. Efficacy of minocycline in acute ischemic stroke：a single-blinded，placebo-controlled trial[J]. Neurol India，2012，60（1）：23-28.
[25] AMIRI-NIKPOUR M R，NAZARBAGHI S，HAMDI-HOLASOU M，et al. An open-label evaluator-blinded clinical study of minocycline neuroprotection in ischemic stroke：gender-dependent effect[J]. Acta Neurol Scand，2015，131（1）：45-50.
[26] SHAMSAEI G，MOHAMMADI P. Effect of oral minocycline on clinical recovery process in patients with acute ischemic stroke：a randomized clinical trial[J/OL]. Jundishapur J Nat Pharm Prod，2017，12（3）：e63792[2026-03-15]. https://doi.org/10.5812/jjnpp.63792.
[27] SINGH R，AUGUSTIN S J，JANE M，et al. Does minocycline improve recovery after acute ischemic stroke？[J]. J Stroke Med，2019，2（1）：40-46.
[28] KOHLER E，PRENTICE D A，BATES T R，et al. Intravenous minocycline in acute stroke：a randomized，controlled pilot study and meta-analysis[J]. Stroke，2013，44（9）：2493-2499.
[29] LU Y，GUAN L，WU J L，et al. Efficacy and safety of minocycline in patients with acute ischaemic stroke（EMPHASIS）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2026，407（10529）：679-688.
[30] SAVITZ S I，BARON J C，FISHER M，et al. Stroke treatment academic industry roundtable Ⅹ：brain cytoprotection therapies in the reperfusion era[J]. Stroke，2019，50（4）：1026-1031.
[31] LIU Z Y，FAN Y，WON S J，et al. Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia[J]. Stroke，2007，38（1）：146-152.
[32] ZHAO Y，XIAO M，HE W B，et al. Minocycline upregulates cyclic AMP response element binding protein and brain-derived neurotrophic factor in the hippocampus of cerebral ischemia rats and improves behavioral deficits[J/OL]. Neuropsychiatr Dis Treat，2015：507-516[2026-03-15]. https://doi.org/10.2147/NDT.S73836.
[33] CHO K O，LA H O，CHO Y J，et al. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion[J]. J Neurosci Res，2005，83（2）：285-291.
[34] CHENG B，LIU S Q，GAO L，et al. Long‐term minocycline treatment exhibits enhanced therapeutic effects on ischemic stroke by suppressing inflammatory phenotype of microglia through the EMB/MCT4/STING pathway[J/OL]. CNS Neurosci Ther，2025，31（3）：e70328[2026-03-15]. https://doi.org/10.1111/cns.70328.
[35] CAI Z Y，YAN Y，SUN S Q，et al. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion[J]. Neurosci Bull，2008，24（5）：305-313.
[36] HAYAKAWA K，MISHIMA K，NOZAKO M，et al. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism[J]. Stroke，2008，39（3）：951-958.
[37] GORDON P H，MOORE D H，MILLER R G，et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis：a phase Ⅲ randomised trial[J]. Lancet Neurol，2007，6（12）：1045-1053.
[38] HOWARD R，ZUBKO O，BRADLEY R，et al. Minocycline at 2 different dosages vs. placebo for patients with mild Alzheimer disease：a randomized clinical trial[J]. JAMA Neurol，2020，77（2）：164-174.
[39] JIN X C，LIU J，LIU K J，et al. Normobaric hyperoxia combined with minocycline provides greater neuroprotection than either alone in transient focal cerebral ischemia[J/OL]. Exp Neurol，2013，240：9-16[2026-03-15]. https://doi.org/10.1016/j.expneurol.2012.11.018.
[40] JIANG Z，ALAMURI T T，MUIR E R，et al. Longitudinal multiparametric MRI study of hydrogen-enriched water with minocycline combination therapy in experimental ischemic stroke in rats[J/OL]. Brain Res，2020，1748：147122[2026-03-15]. https://doi.org/10.1016/j.brainres.2020.147122.
[41] WANG C X，YANG T，SHUAIB A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke[J]. Brain Res，2003，963（1/2）：327-329.
[42] CHO D Y，JEUN S S. Combination therapy of human bone marrow-derived mesenchymal stem cells and minocycline improves neuronal function in a rat middle cerebral artery occlusion model[J/OL]. Stem Cell Res Ther，2018，9：309[2026-03-15]. https://doi.org/10.1186/s13287-018-1011-1.
[43] SOLIMAN S，ISHRAT T，FOUDA A Y，et al. Sequential therapy with minocycline and candesartan improves long-term recovery after experimental stroke[J]. Transl Stroke Res，2015，6（4）：309-322.
[44] YU I C，KUO P C，YEN J H，et al. A combination of three repurposed drugs administered at reperfusion as a promising therapy for postischemic brain injury[J]. Transl Stroke Res，2017，8（6）：560-577.
[45] RAHMANI M，NEGRO ÁLVAREZ S E，HERNÁNDEZ E B. The potential use of tetracyclines in neurodegenerative diseases and the role of nano-based drug delivery systems[J/OL]. Eur J Pharm Sci，2022，175：106237[2026-03-15]. https://doi.org/10.1016/j.ejps.2022.106237.
[46] FU Z Q，HAI N，ZHONG Y H，et al. Printing GelMA bioinks：a strategy for building in vitro model to study nanoparticle-based minocycline release and cellular protection under oxidative stress[J/OL]. Biofabrication，2024，16（2）[2026-03-15]. https://doi.org/10.1088/1758-5090/ad30c3.
[47] CHENG G W，LIU Z W，YAN Z，et al. Minocycline nanoplatform penetrates the BBB and enables the targeted treatment of Parkinson’s disease with cognitive impairment[J/OL]. J Control Release，2025，377：591-605[2026-03-15]. https://doi.org/10.1016/j.jconrel.2024.11.066.
[48] WU D，ZHOU J，ZHENG Y R，et al. Pathogenesis-adaptive polydopamine nanosystem for sequential therapy of ischemic stroke[J/OL]. Nat Commun，2023，14：7147[2026-03-15]. https://doi.org/10.1038/s41467-023-43070-z.
[49] MAZZITELLI J A，PULOUS F E，SMYTH L C D，et al. Skull bone marrow channels as immune gateways to the central nervous system[J]. Nat Neurosci，2023，26（12）：2052-2062.

米诺环素在急性缺血性卒中中的抗神经炎症与脑细胞保护研究进展：从机制到临床证据

Research Progress on the Anti-Neuroinflammatory Effects and Brain Cytoprotection of Minocycline in Acute Ischemic Stroke: From Mechanisms to Clinical Evidence

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	林金嬉, 李上智, 张艳丽, 高培元, 周宏宇. 糖尿病病程与Lp-PLA2活性对急性缺血性卒中临床结局的影响分析[J]. 中国卒中杂志, 2026, 21(6): 703-711.
[2]	崔钰, 王璐, 陈会生. 急性缺血性卒中患者替奈普酶静脉溶栓治疗的良好预后影响因素分析[J]. 中国卒中杂志, 2026, 21(6): 712-718.
[3]	孔祥慧, 樊雅妮, 韩德昌, 李光民, 卢雅丹, 刘玉兰, 陈丽丽. 老年前循环轻型急性缺血性卒中预后影响因素分析[J]. 中国卒中杂志, 2026, 21(6): 740-745.
[4]	龚小沉, 李肇坤, 邹新宇, 左家财, 唐宇凤. TNNI3基因突变致肥厚型心肌病为首因的青年急性缺血性卒中1例报道及系谱分析 [J]. 中国卒中杂志, 2026, 21(6): 782-787.
[5]	何丹丹, 李俭, 王春娟, 李姝雅. 我国急性缺血性卒中脑细胞保护剂基础实验与临床研究的挑战与突破[J]. 中国卒中杂志, 2026, 21(5): 517-524.
[6]	程希玥, 赵璟妍, 王春娟. 依达拉奉右莰醇在急性缺血性卒中脑细胞保护中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 526-532.
[7]	何丹丹, 李姝雅. 基于STAIR原则的PSD-95靶向脑细胞保护剂在急性缺血性卒中中的研究进展[J]. 中国卒中杂志, 2026, 21(5): 543-552.
[8]	陈壮壮, 徐柳, 王楠星, 张眉扬, 姬若冰, 杨沫, 刘向荣, 王伊龙. 经颅骨骨髓途径递送脑细胞保护剂的研究与展望[J]. 中国卒中杂志, 2026, 21(5): 553-560.
[9]	陈玮琪, 江凌玲, 何菂, 陈彦博, 张枘南, 刘欣如, 刘文竹, 郭蕾, 王玲, 王伊龙. 干细胞衍生物：突破活细胞治疗局限的多靶点脑细胞保护生物制品[J]. 中国卒中杂志, 2026, 21(5): 561-569.
[10]	常曹文静, 许淑红, 李俭, 李姝雅. 载脂蛋白E基因与缺血性卒中后脑损伤关系的研究进展[J]. 中国卒中杂志, 2026, 21(5): 570-576.
[11]	李汶逸, 姜季委, 任琦玮, 王琳琳, 赵敏, 徐俊. 载脂蛋白E基因多态性与卒中后认知功能变化的相关性研究[J]. 中国卒中杂志, 2026, 21(5): 577-584.
[12]	刘元昊, 吴磊, 杨欢, 朱佳颖, 李亚哲. 不同取栓装置在急性缺血性卒中治疗中的有效性与安全性：1项回顾性比较研究[J]. 中国卒中杂志, 2026, 21(4): 463-470.
[13]	欧茹, 刘益民, 徐智坚, 黄文纯. 血管源性腔隙灶对急性缺血性卒中患者生命健康状况的动态影响[J]. 中国卒中杂志, 2026, 21(3): 312-319.
[14]	李荔, 段振晖, 高爱华, 潘宋斌. 老年急性缺血性卒中患者衰弱指数、营养风险与静脉溶栓后院内感染风险的相关性分析及预测模型构建[J]. 中国卒中杂志, 2026, 21(3): 331-337.
[15]	张自立, 赵颖, 孟珩, 徐安定. 急性缺血性卒中血管内治疗后无效再通预测研究进展[J]. 中国卒中杂志, 2026, 21(3): 378-386.